NIB shares could be going to $8 and beyond: brokers

This private health insurer has been given the thumbs up by a couple of brokers.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares are ending the week in a positive fashion.

In late trade, the health insurer's shares are up 1% to $7.55.

This latest gain means that its shares are now up over 9% since this time last year.

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.

Image source: Getty Images

Can NIB shares keep rising?

The good news is that a number of brokers believe that NIB shares can continue their ascent over the next 12 months.

For example, according to a note out of Citi from last week, its analysts have upgraded its shares to a buy rating with a $8.35 price target.

Citi has been pleased with the company's performance this year and feels that it is well-placed to manage claims inflation. It said:

With arhi reporting stronger growth than at this stage a year ago and decent momentum in iihi and NZ, we believe nib looks attractive. Claims inflation is likely picking up with some out of cycle contract renegotiation with hospitals. However, we believe nib should be in a strong position to manage this, at least in the shorter term.

Elsewhere, the team at Goldman Sachs sees scope for NIB shares to rise a touch higher. Last week, it retained its buy rating with an $8.40 price target. This implies an 11% upside from current levels. The broker said:

We currently have a preference for NHF in this space reflecting strong underlying top line growth through policyholder growth and premium rate increases, shareholder-friendly interpretation to not profit from Covid-19, while offering greater diversity of earnings outside of regulated resident health insurance.

It is also worth highlighting that Citi and Goldman Sachs both expect attractive dividend yields in FY 2024. They have pencilled in fully franked dividends per share of 30 cents and 28.8 cents, which equate to yields of 4% and 3.8%, respectively.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Morgans names 2 ASX shares to buy and 1 to accumulate

What is the broker recommending investors do with these shares?

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

2 ASX 200 shares to buy ahead of anticipated rally: expert

After a 9.1% drop between 27 February and 23 March, the ASX 200 reversed course last Tuesday.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

Bell Potter says this ASX 200 stock can rise 38% and pay a 6% dividend yield

Major upside and a generous dividend yield could be on offer with this name.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

Is this ASX defence stock the next DroneShield?

Bell Potter thinks this stock could be the next to rocket. Let's find out why.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Broker Notes

This ASX healthcare stock could almost double in value according to Bell Potter

The broker believes this stock is making major breakthroughs.

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

a miner holds his thumb up as he holds a device in his other hand.
Resources Shares

Experts name 3 ASX mining shares to buy after March sell-off

Investors took profits amid fears the fuel crisis could impact miners' production and earnings.

Read more »